The eSTAR Submission Program for 510(k)s, IDEs, De Novos, PMAs, and Q-Submissions

Description

This webinar will discuss current US Federal law on the 510(k), IDE, DeNovo, and PMA and associated requirements for getting a new or substantially changed medical device through the US FDA review process and to market in the USA. US law and the FDA require that a device be the subject of an approved marketing application before it is transported or distributed across state lines. While ultimately all submissions will be by electronic means under the FDA's eSTAR submission template, currently only 510(k) have a final submission eSTART submission guidance, required to be used as of October 1, 2023. Other templates will be released in the future. Two Guidance documents, 1) a "Parent" / covering guidance discusses the entire eSTAR program for all types of submissions, and 2) the first, now finalized and operative as of October 2023, specific Guidance template, for 510(k)s, under the eSTAR program.

Why Should You Attend:

For decades, the regulation and control of new or substantially changed medical devices for sale in the United States (no matter where manufactured has been based on a paper and e-copy 510(k), PMA or DeNovo submission and FDA review process. That has all changed as of October 2023. Now a 510(k) clearance for Class II devices required prior to commercialization, can only be submitted for review through the Agency's new eSTAR portal. IDEs, DeNovos, or of a higher risk requiring clinicals, the PMA, will be required to be submitted electronically through eSTAR at later dates as new guidance templates for each are published by the Agency. The 510(k) process has had some recient modification to allow for newer technology (Breakthrough) or increased safety (STeP). And new Cybersecurity, Machine Learning and Artificial Intelligence features add additional complexity to the process.

Areas Covered in the Webinar:

• The new eSTAR Device Submissions and the US FDA

• The 510(k) process
• The "Parent" eSTAR Guidance
• The first specific Guidance, the 510(k) eSTAR Submission Template

• Cybersecurity Submission Requirements

• New 510(k) Mod program and Q-Sub

• Machine Learning and Artificial Intelligence Issues - FDA "Principles"

• Post-market requirements

Who Will Benefit:

• Senior management in Devices, Combination Products
• QA / RA
• Medical Device product development teams
• R&D
• Engineering
• Production
• Operations
• Marketing
• Consultants; others tasked with device product development, manufacturing, process / product / data analysis, regulatory submission responsibilities

John E Lincoln
Principal, J E Lincoln and Associates

John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 41 years experience in U.S. FDA-regulated industries, 27 years as head of his own consulting company. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, 5 chapters in the RAPS textbook on validation, conducted workshops and webinars worldwide on CGMP subjects. John is a graduate of UCLA.

Follow us :